๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hirosaki
Clinical trial register · Japan

Clinical Trials in Hirosaki, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 2472 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
2472
Studies in scope
all four open statuses
1255
Recruiting now
open to new participants
347
Lead sponsors
across recruiting studies
Top sites
Fukuoka 550 Nagoya 510 Sapporo 402 Tokyo 363 Osaka 345
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC8 Eli Lilly and Company6 Janssen Research & Development, LLC6 AbbVie5 Sanofi2
Site location
Fukuoka550 Nagoya510 Sapporo402 Tokyo363 Osaka345
All 929 locations
Target enrolment
to

Trials with a site in Hirosaki

44 of 2472 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241Small Cell Lung Cancer
DrugsABBV-706·Amrubicin·Lurbinectedin·Topotecan
AbbVie
Phase 3
531
Toyoake, Hirosaki, Fukuoka, Sapporo, Kobe, Sagamihara-shi, Sendai, Niigata
2026-07-02
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
460
Hamamatsu, Hirosaki, Kagoshima, Kashiwa, Kobe, Kumamoto, Minatoku, Nagoya
2026-05-22
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Nagoya, Seto, Hirosaki, Asahi, Funabashi, Matsudo, Kitakyushu, ลŒgaki
2026-05-11
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
590
Nagoya, Hirosaki, Tลon, Sapporo, Kobe, Tsukuba, Kita-gun, Kawasaki
2026-04-23
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Asahikawa, Bunkyล City, Fujiidera, Fukuoka, Hirosaki, Kagoshima, Kashiwa, Mitaka
2026-03-26
Recruiting
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07179380Pulmonary Hypertension, Interstitial Lung Disease
DrugTreprostinil Palmitil
Insmed Incorporated
Phase 3
344
Nagakute, Seto, Hirosaki, Narashino-shi, Narita-shi, Sapporo, Yokohama, Kyotoshi
2026-01-07
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Chลซลku, Fukuoka, Hirosaki, Kanazawa, Kashiwa, Kawasaki, Kita-ku, Kobe
2025-12-12
Recruiting
Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
NCT07136116Ulcerative Colitis
AbbVie
Observational
200
Nagakute, Nagoya, Hirosaki, Chiba, Kashiwa-shi, Sakura, Fukuoka, Hiroshima
2025-10-09
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Calderasib·Pemetrexed·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
675
Nagoya, Toyoake, Hirosaki, Tลon, Kurume, ลŒta, Himeji, Kobe
2025-10-08
Recruiting
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
NCT07204314Major Depressive Disorder
DrugVortioxetine
Takeda
Phase 3
180
Nagoya, Hirosaki, Chลซลku, Shirakawa, Sapporo, Zentsujichรณ, Kawasaki, Yokohama
2025-10-01
Active, closed
Fabhalta Capsules Specified Drug-use Survey
NCT07156149C3 Glomerulopathy
Novartis Pharmaceuticals
Observational
33
Nagoya, Toyoake, Hirosaki, Chiba, Fukuoka, Kitakyushu, Sapporo, Tsukuba
2025-09-17
Recruiting
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
NCT06975722Ulcerative Colitis
DrugSAR442970
Sanofi
Phase 2
99
Kashiwa, ลŒita, Hamamatsu, Hirosaki, Morioka, Nishinomiya
2025-07-07
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
DrugSAR442970
Sanofi
Phase 2
99
Kashiwa, ลŒita, Hamamatsu, Bunkyล City, Hirosaki, Morioka, Nishinomiya
2025-06-03
Active, closed
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080Diabetic Macular Edema (DME)
DrugsRestoret·Ranibizumab
EyeBiotech Ltd.
Phase 2/3
1,054
Nagoya, Hirosaki, Sakura, Yoshida-gun, Fukuoka, Kurume, Asahikawa, Amagasaki
2025-04-16
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin
AbbVie
Phase 1/2
252
Nagoya, Hirosaki, Yokohama, Kyoto, Niigata, Takatsuki, Chuo-Ku, Koto-ku
2025-03-06
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
NCT06632951Urothelial Carcinoma
DrugsLivmoniplimab·Budigalimab·Docetaxel·Gemcitabine
AbbVie
Phase 2
150
Hirosaki, Fukushima, Tsukuba, Kanazawa
2025-01-20
By invitation
Obtain Safety and Effectiveness of CT-ACL001, a Regenerative Ligament Using Biological Tissue, in ACLR
NCT07129694Anterior Cruciate Ligament Rupture
CoreTissue BioEngineering Inc.
Not applicable
64
Hirosaki, Hiroshima, Sapporo, Kobe, Bunkyo-ku, Shinjuku-ku
2024-11-25
Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic
DrugsEltrekibart·Mirikizumab
Eli Lilly and Company
Phase 2
143
Chiba, Chikushino-shi, Fukuoak, Hachinohe-shi, Hirosaki, Hiroshima, Isehara, Isesaki-shi
2024-10-10
Recruiting
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
NCT06476184Ovarian Cancer
DrugsPaclitaxel·Carboplatin
ARCAGY/ GINECO GROUP
Phase 3
250
Bunkyล City, Fukushima, Hidaka, Hirosaki, Kashiwa, Kawasaki, Koshigaya, Kurume
2024-07-30
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSacituzumab tirumotecan·Keytruda·Nab-paclitaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
851
Nagoya, Toyoake, Hirosaki, Kashiwa, Tลon, ลŒta, Kobe, Takarazuka
2024-06-10
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
120
Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya Ku, Tokyo
2024-03-13
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
90
Bunkyล City, Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya-ku
2024-03-13
Active, closed
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275Crohn's Disease
AbbVie
Observational
1,200
Nagoya, Toyoake, Hirosaki, Chiba, Sakura, Fukuoka, Fukushima, Asahikawa-shi
2024-02-19
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Toyoake, Hirosaki, Kashiwa, Matsuyama, Fukuoka, Kurume, ลŒta, Himeji
2023-12-15
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Nagoya, Hirosaki, Kashiwa, Akashi, Kawasaki, Yokohama, Sendai, Hirakata
2023-12-06
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
1,600
Aichi, Fukuoka, Hirosaki, Hiroshima, Hokkaido, Kashihara, Matsumoto, Miyagi
2023-10-26
Recruiting
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
NCT05646511Locally Advanced Rectal Cancer
DrugFolfox
National Cancer Center Hospital East
Phase 3
608
Chiba, Ehime, Fukuoka, Gifu, Hirosaki, Hiroshima, Kawasaki, Kitakyushu
2022-11-21
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
577
Asahikawa, Bunkyล City, Chikushino-shi, Fukuoka-ken, Gifu, Hachiลji, Hamamatsu, Hirosaki
2022-09-19
Recruiting
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
NCT05392764Acute Heart Failure
DrugDapagliflozin
Juntendo University
Phase 3
444
Anjo, Nagakute, Nagoya, Hirosaki, Sumoto, Funabashi, Kamogawa, Urayasu
2022-09-10
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
703
Asahikawa, Bunkyล City, Chikushino-shi, Fukuoka, Hachiลji, Hamamatsu, Hirosaki, Hitachi
2022-07-22
Active, closed
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT04738942Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
56
Toyota, Hirosaki, Kashiwa, Sakura, Chikushino-shi, Sapporo, Nishinomiya, Kamakura
2021-06-04
Active, closed
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622Prostate Cancer
DrugsTalazoparib·Enzalutamide
Pfizer
Phase 3
599
Nagoya, Hirosaki, Chiba, Kashiwa, Matsuyama, Fukuoka, Kure, Sapporo
2021-05-12
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
808
Nagoya, Hirosaki, Tsukuba, Kanazawa, Sagamihara, Yokohama, Sendai, Hamamatsu
2021-04-21
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma
DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate
Exelixis
Phase 3
575
Toyota-shi, Akita, Hirosaki, Kashiwa-shi, Sakura-shi, Sapporo, Kobe, Kita-gun
2020-10-19
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
996
Hirosaki, Kashiwa, Kitakyusyu-shi, Chikushino-shi, Fukuoka, Kiryลซ, Chuo-ku, Sapporo-shi, Sapporo
2020-06-22
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04241185Urinary Bladder Neoplasms
DrugsMitomycin C·5-FU·Fluorouracil·Keytruda
Merck Sharp & Dohme LLC
Phase 3
520
Hirosaki, Tsukuba, Takatsuki, Nagasaki, Tokyo
2020-05-19
Active, closed
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
NCT04223856Urothelial Cancer
DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin
Astellas Pharma Global Development, Inc.
Phase 3
886
Bunkyล City, Chiba, Fukuoka, Hirosaki, Kawasaki-shi, Kลtoku, Kyoto, Niigata
2020-03-30
Active, closed
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244Prostatic Neoplasms
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
2,517
Akita, Chiba, Chลซลku, Hakodate, Hirosaki, Kanazawa, Kobe, Koshigaya
2019-06-11
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
DrugsKeytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,397
Hirosaki, Tลon, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Kashihara, Hamamatsu
2018-12-24
Active, closed
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03706365Prostate Cancer
DrugsAbiraterone acetate·Abemaciclib·Prednisone
Eli Lilly and Company
Phase 2/3
393
Nagoya, Hirosaki, Sakura, Sapporo, Kobe, Kanazawa, Yokohama, Ina-machi
2018-11-26
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
629
Chiba, Hirosaki, Kashiwa, Kita Gun, Kobe, Koshigaya, Matsuyama, Miyazaki
2018-03-23
Active, closed
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197mCRPC
Pfizer
Phase 3
1,054
Nagoya, Hirosaki, Kashiwa, Matsuyama, Kure, Sapporo, Kanazawa, Yokohama
2017-12-18
Active, closed
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03036098Urothelial Cancer
DrugsIpilimumab·Nivolumab·Gemcitabine·Cisplatin
Bristol-Myers Squibb
Phase 3
1,314
Hirosaki, Chiba, Matsuyama, Fukuoka, Sapporo, Tsukuba, Morioka, Kita-Gun
2017-03-24
Active, closed
Japanese Idiopathic Interstitial Pneumonias Registry
NCT03041623Idiopathic Interstitial Pneumonia
North East Japan Study Group
Observational
867
Kiyosu, Nagoya, Seto, Toyoake, Hirosaki, Chiba, Kamogawa, Matsuyama
2016-12
Rows per page Showing 1–44 of 44
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-japan/city/hirosaki

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,472 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 44 of those studies with a site in Hirosaki.

How many clinical trials are recruiting in Hirosaki?

22 of the 44 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 0 have not yet opened recruitment, 21 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hirosaki), 44 studies
PhaseStudiesRecruitingShare
Phase 3291665.9%
Phase 27415.9%
Observational419.1%
Phase 2/3204.5%
Not applicable102.3%
Phase 1/2112.3%

Most active sponsors

Lead sponsors with the most studies (Hirosaki)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC84
Eli Lilly and Company64
Janssen Research & Development, LLC62
AbbVie53
Novartis Pharmaceuticals21
Pfizer20
Sanofi22
Takeda21
ARCAGY/ GINECO GROUP11
Astellas Pharma Global Development, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.